Knowledge Center
Explore our library of blogs, short videos, virtual event recordings and training topics
Recent Blogs
Approval of OA REMS Advancement
The U.S. Food and Drug Administration (FDA) announced today, October 31, 2024, that it has approved a modification to the Opioid Analgesic Risk Evaluation and Mitigation Strategy (OA REMS). This modification aims to provide patients and caregivers with a free, pre-paid drug mail-back envelope from outpatient pharmacies or other dispensers of opioid analgesics.
Webinar Recap | CARES Act Reporting: Strategies for Efficient Submissions
As most drug companies are aware of at this point, the CARES Act requires drug manufacturers to report annual production amounts to the FDA. This requirement has been rolling out over the course of 2024 and, here at LexisNexis Reed Tech, we are receiving many questions from our customers have had questions about how to meet these requirements. As such, we presented a webinar CARES Act Reporting: Strategies for Efficient Submissions covering the requirements, timelines and strategies for efficient reporting. The webinar was presented by LexisNexis Reed Tech subject-matter experts Gary Saner, Senior Regulatory Principal, Life Sciences.
LexisNexis Reed Tech and 1WorldSync Webinar Recap: Leveraging UDI and GDSN
On Tuesday, October 15, 2024, Reed Tech and 1WorldSync hosted a highly informative webinar led by Gary Saner, Senior Regulatory Principal at Reed Tech, and Scott Brown, Senior Director of Global Data Strategy at 1WorldSync. The webinar focused on how their continued alliance helps companies navigate Unique Device Identification (UDI) management and utilize the Global Data Synchronization Network (GDSN) to meet regulatory compliance requirements.
UDI Regulations from EUDAMED, MDR, FDA, and other Global Health Authorities
In recent years, Unique Device Identification (UDI) regulations have been a focus topic for global health authorities. These regulations enhance patient safety, improve supply chain management, and facilitate efficient medical device recalls. Read on for a recap of recent updates and expected changes to UDI regulations from global health authorities.
Takeaways from RAPS Convergence 2024: Navigating the Evolving Landscape of Medical Device Regulations and Digital Transformation
Navigating the Evolving Landscape of Medical Device Regulations and Digital Transformation
Effective 10/1/24, New FDA Requirements for Listing OTC Monograph Drugs in eDRLS
The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) has introduced reforms to the OTC drug review process. Starting October 1, 2024, the listing of OTC monograph drug products will require the use of the current Marketing Category and Application Number values in the FDA’s Electronic Drug Registration and Listing System (eDRLS), and will not be able to be certified under the old marketing categories and old application number fields.